Compare LADR & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LADR | TNDM |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2013 | 2013 |
| Metric | LADR | TNDM |
|---|---|---|
| Price | $10.15 | $15.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 19 |
| Target Price | $12.25 | ★ $28.00 |
| AVG Volume (30 Days) | 551.6K | ★ 2.6M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | $31.66 | $8.11 |
| Revenue Next Year | $16.92 | $11.85 |
| P/E Ratio | $506.75 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $9.61 | $10.00 |
| 52 Week High | $11.92 | $29.65 |
| Indicator | LADR | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 41.36 |
| Support Level | $9.90 | $12.75 |
| Resistance Level | $10.54 | $15.75 |
| Average True Range (ATR) | 0.14 | 1.25 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 55.10 | 37.19 |
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments: Loans, which derive maximum revenue; Securities; and Real Estate.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.